
New AACR-Novocure Funding Initiatives Support Tumor Treating Fields Research
Earlier this year, the American Association of Cancer Research (AACR) partnered with Novocure, a global oncology company, to launch...
Home »
Earlier this year, the American Association of Cancer Research (AACR) partnered with Novocure, a global oncology company, to launch...
There has been an explosion in the number of cancer therapeutics and clinical trials in the recent past, owing...
After three decades of failed efforts to target the elusive KRAS and its family members NRAS and HRAS, proto-oncogenes...
Shenzhen is a remarkable place. It serves as a gateway to Hong Kong, and in its short 40-year history...
Hot on the heels of the FDA’s landmark approval of an anticancer therapeutic for use based on whether a...
Finding a way to therapeutically target the so-called “undruggable” cancer proteins has long been a holy grail of researchers...
The American Association for Cancer Research (AACR) will host its first ever Special Conference on Engineering and Physical Sciences...
This post explores the challenges we face with anti-EGFR monoclonal antibody therapies and new strategies researchers have developed to...
Currently, anti-EGFR therapies are approved by the U.S. Food and Drug Administration for the treatment of non-small cell lung...
The National Cancer Institute’s Lee Helman, MD, co-chair of the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, discusses...